Kura Oncology Inc (NASDAQ: KURA) closed the day trading at $18.59 down -2.21% from the previous closing price of $19.01. On the day, 821071 shares were traded.
Ratios:
For a better understanding of KURA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.26 and its Current Ratio is at 12.26. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on December 22, 2023, initiated with a Buy rating and assigned the stock a target price of $26.
On August 11, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $31.
On July 27, 2023, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $10.50.Scotiabank initiated its Sector Perform rating on July 27, 2023, with a $10.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 30 ’24 when DALE STEPHEN sold 4,825 shares for $21.55 per share. The transaction valued at 103,980 led to the insider holds 38,817 shares of the business.
DALE STEPHEN sold 7,158 shares of KURA for $127,416 on Jan 29 ’24. The Chief Medical Officer now owns 43,642 shares after completing the transaction at $17.80 per share. On Jan 29 ’24, another insider, DOYLE THOMAS JAMES, who serves as the SVP, Finance & Accounting of the company, sold 2,318 shares for $17.80 each. As a result, the insider received 41,262 and left with 48,093 shares of the company.
Stock Price History:
Over the past 52 weeks, KURA has reached a high of $24.17, while it has fallen to a 52-week low of $7.41.
Shares Statistics:
A total of 74.35M shares are outstanding, with a floating share count of 63.54M. Insiders hold about 16.54% of the company’s shares, while institutions hold 90.26% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$0.68, while EPS last year was -$0.5. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.51 and low estimates of -$0.68.
Analysts are recommending an EPS of between -$2 and -$2.92 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is -$2.46, with 13 analysts recommending between -$1.94 and -$3.1.
